erlotinib hydrochloride has been researched along with ketoconazole in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ketoconazole) | Trials (ketoconazole) | Recent Studies (post-2010) (ketoconazole) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,202 | 706 | 1,269 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charoin, JE; Fettner, S; Hamilton, M; Jones, HM; Lum, BL; Pantze, MP; Rakhit, A; Riek, M | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
| Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z | 1 |
| Banpurkar, AR; Perdih, F; Wazalwar, SS | 1 |
1 trial(s) available for erlotinib hydrochloride and ketoconazole
| Article | Year |
|---|---|
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Topics: Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Erlotinib Hydrochloride; Forecasting; Humans; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
4 other study(ies) available for erlotinib hydrochloride and ketoconazole
| Article | Year |
|---|---|
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Biological; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Rivaroxaban; Venous Thromboembolism | 2022 |
Synthesis, crystal structure and molecular docking study of novel isoxazole derivatives as CYP450 inhibitors in search of anticancer agents.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Isoxazoles; Ketoconazole; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |